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Abbreviations: ABCA1 = ATP-binding cassette transporter A1; ACS = acute coronary 
syndrome; ADCY9 = adenylate cyclase 9; apo = apolipoprotein; CETP = cholesteryl ester 
transfer protein; CAD = coronary artery disease; CHD = coronary heart disease; CKD = chronic 
kidney disease; eNOS = endothelial nitric oxide synthase; GPCRs = G-protein-coupled 
receptors; HDL = high-density lipoproteins; HOCl = hypochlorous acid; ICAM-1 = 
intracellular cell adhesion molecule 1; IL = interleukin; IVUS = intravascular ultrasound; 
LCAT = lecithin:cholesterol acyltransferase; LDL = low-density lipoproteins; LOX-1 = lectin-
like oxidized LDL receptor-1; MDA = malonaldehyde;  miRNA = microRNA; MMP-9 = matrix 
metalloproteinase 9; PON1 = paraoxonase 1; PAPC = 1-palmitoyl-2-arachidonyl-sn-glycero-3-
phosphocholine; PLPC = 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine; POPC = 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; PPAR-α = peroxisome proliferator activator 
receptor alpha; rHDL  = reconstituted HDL; S1P = sphingosine-1-phosphate; SAA = serum 
amyloid A; SDMA = symmetric dimethylarginine;  SR-BI = scavenger receptor class B type I; 
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STEMI = ST-elevation myocardial infarction; TLR = toll-like receptor; TNF-α= tumor necrosis 
factor α; VCAM-1 = vascular cell adhesion molecule 1.    
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Abstract 
Low plasma levels of high-density lipoprotein (HDL) cholesterol are associated with increased 
risks of coronary heart disease (CHD). HDL mediates cholesterol efflux from macrophages for 
reverse transport to the liver and elicits many anti-inflammatory and anti-oxidative activities 
which are potentially anti-atherogenic. Nevertheless, HDL has not been successfully targeted 
by drugs for prevention or treatment of cardiovascular diseases. One potential reason is the 
targeting of HDL cholesterol which does not capture the structural and functional complexity 
of HDL particles.  Hundreds of lipid species and dozens of proteins as well as several 
microRNAs have been identified in HDL. This physiological heterogeneity is further increased 
in pathological conditions due to additional quantitative and qualitative molecular changes of 
HDL components which have been associated with both loss of physiological function and gain 
of pathological dysfunction. This structural and functional complexity of HDL has prevented 
clear assignments of molecules to the functions of normal HDL and dysfunctions of 
pathological HDL. Systematic analyses of structure-function-relationships of HDL-associated 
molecules and their modifications are needed to test the different components and functions of 
HDL for their relative contribution in the pathogenesis of atherosclerosis. The derived 
biomarkers and targets may eventually help to exploit HDL for treatment and diagnostics of 
cardiovascular diseases.  
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Introduction 
According to epidemiological, pathophysiological, genetic, and clinical evidence dyslipidemias 
play an important pathogenic role in the development of atherosclerosis. Notably, low-density 
lipoprotein (LDL)-cholesterol lowering by the use of statins has become one of the most 
successful developments in preventive medicine since they help to reduce coronary heart 
disease (CHD) event rates by up to 50% in the highest dosage.1 Besides intensified LDL-
cholesterol lowering, increasing of high-density lipoprotein (HDL)-cholesterol has been 
another interesting target for cardiovascular risk reduction for a long time. Many clinical and 
epidemiological studies as well as meta-analyses thereof have shown the inverse relationship 
of HDL-cholesterol plasma levels with the risk of CHD.2 Furthermore, the development of 
atherosclerotic lesions could be decreased or even reverted in several animal models by 
transgenic over-expression or exogenous application of apolipoprotein A-I (apoA-I), that is the 
most abundant protein of HDL.3 
For LDL-cholesterol and high blood pressure this type of epidemiological and biological 
evidence has been successfully translated into drugs that lower CHD risk. To date, however, it 
has been proven difficult to successfully reduce CHD risk with drugs increasing HDL-
cholesterol such as fibrates, niacin, or inhibitors of cholesteryl ester transfer protein (CETP).4, 
5 Moreover, in several inborn errors of human HDL metabolism and genetic mouse models with 
altered HDL metabolism, the changes in HDL-cholesterol levels were not associated with the 
opposite changes in cardiovascular risk and atherosclerotic plaque load, respectively, expected 
from epidemiological studies.3, 6 Because of these controversial data, the causal role and hence 
suitability as a therapeutic target of HDL has been increasingly questioned.  
 However, previous intervention and genetic studies targeted LDL-cholesterol and HDL-
cholesterol, that is the cholesterol measured by clinical laboratories in LDL and HDL, 
respectively. By contrast to the pro-atherogenic and hence disease causing cholesterol in LDL 
(that is LDL-cholesterol), which after internalization turns macrophages of the arterial intima 
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into pro-inflammatory foam cells, the cholesterol in HDL (that is HDL-cholesterol) neither 
exerts nor reflects any of the potentially anti-atherogenic activities of HDL. By contrast to LDL-
cholesterol, HDL-cholesterol is only a non-functional surrogate marker for estimating HDL 
particle number and size without deciphering the heterogeneous composition and hence 
functionality of HDL.5 In a prototypic HDL particle two to five molecules of apoA-I and about 
100 molecules of phosphatidylcholine form an amphipathic shell in which several molecules of 
un-esterified cholesterol are imbedded and which surrounds a core of completely water-
insoluble cholesterol esters, albeit less, triglycerides. Already molar differences in the content 
of the major protein and lipid constituents of HDL, that is apoA-I, phosphatidylcholine, 
sphingomyelin, cholesterol, and cholesteryl esters, cause considerable heterogeneity of HDL in 
shape, size, and charge.5 Some of these model particles have been artificially reconstituted for 
experimental but also therapeutic purposes.7 This macro-heterogeneity is further increased by 
the presence or absence of quantitatively minor proteins or lipids, some of which may contribute 
to the pleiotropic functions of HDL. Previous proteomic and lipidomic studies revealed a much 
greater structural complexity: HDL particles carry more than eighty different proteins and 
hundreds of lipid species.8 Most recently, even microRNAs (miRNAs) were found to be 
transported by HDL.9, 10 Many of these molecules are not passive cargo but biologically active 
and contribute to the pleiotropic and potentially anti-atherogenic properties of HDL. This 
micro-heterogeneity is further increased in HDL of patients with various inflammatory 
diseases, including CHD, by the loss or structural modification of typical HDL constituents or 
by the acquisition of atypical constituents.5, 11, 12 Of note, many physiological as well as 
pathological components and modifications are present at concentrations which are several 
orders of magnitude lower than the concentration of HDL-cholesterol or even HDL particles 
and hence reflected by measurements of neither HDL-cholesterol, nor apoA-I, nor HDL-
particle concentrations.5  In the search for biomarkers that reflect the functionality of HDL 
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better than these high-throughput markers, bioassays have been developed for clinical studies 
as well as for discovery of functional biomarkers by proteomics and lipidomics.   
 
HDL and protection against cardiovascular disease 
HDL particles exert many beneficial actions that may help protect against cardiovascular 
disease.5, 13  
The classical anti-antherogenic role of HDL in cardiovascular disease is its potential to drive 
cholesterol export from macrophage foam cells and subsequent transport towards the liver for 
excretion into bile and feces, i.e. reverse cholesterol transport.14, 15 HDL elicits the first step, 
cholesterol efflux from macrophages, by several mechanisms and different subclasses. The 
lipid-containing, buoyant, and α-migrating HDL facilitates aqueous diffusion of plasma 
membrane residing cholesterol by tethering to scavenger receptor class B type I (SR-BI). α-
migrating HDL also elicits active cholesterol efflux from intracellular pools by a mechanism 
involving ATP-binding cassette transporter G1 (ABCG1). Although present at very low 
concentrations lipid-free apoA-I, which because of its electrophoretic mobility is termed 
prebeta1-HDL, is a very potent inducer of active cholesterol efflux by ABCA1.4, 5, 13-15 Both 
ABCA1 and ABCG1 are integrated into both positive feed-forward and negative feed-back 
regulation loops of cellular cholesterol homeostasis involving both transcriptional regulation 
by oxysterol-activated nuclear liver X receptors and post-transcriptional regulation by several 
miRNAs. Thus, cholesterol efflux is determined by the extracellular concentration and 
composition of HDL particles as well as by the activity of ABC transporters.4, 5, 13-15 By 
modulating cellular cholesterol homeostasis, both apoA-I and HDL indirectly regulate survival 
and functions of several cell types (Figure 1).4, 5  
Numerous other potential atheroprotective functions of HDL have been described and the list 
is still growing. An important event in the development of atherosclerosis is the modification 
of LDL, notably the formation of oxidized LDL. Many in vitro experiments have indicated that 
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HDL, primarily by its associated components apoA-I and paraoxonase 1 (PON1), has the ability 
to counteract lipid peroxidation of LDL.16-19 Furthermore, HDL functions as a protective factor 
for the vascular endothelium by mechanisms that involve interactions with signaling receptors 
and hence go beyond the regulation of cholesterol homoeostasis or the inhibition of oxidation 
(Figure 1). HDL induces endothelium-dependent vascular relaxation via increased endothelial 
nitric oxide synthase (eNOS) phosphorylation and nitric oxide production,20 and maintains 
endothelial barrier stability by promoting endothelial cell survival,21, 22 stimulating endothelial 
junction closure via HDL-bound sphingosine-1-phosphate (S1P),23, 24 and accelerating 
endothelial cell migration and re-endothelialization of injured arteries.25, 26 Moreover, anti-
inflammatory activities of HDL in atherosclerosis have been documented. HDL attenuates the 
adhesion of monocytes to the vascular endothelial lining and subsequent monocyte 
transendothelial migration by decreasing the expression of adhesion molecules on endothelial 
cells27, 28 and monocytes29 as well as by suppressing the expression of chemokines and 
chemokine receptors.30, 31 Eventual disruption of atherosclerotic lesions initiates platelet 
activation and aggregation. In the presence of HDL platelet activation and aggregation are 
significantly inhibited,32-34 which may in turn lead to reduced thrombus formation.32 Other 
proposed mechanisms by which HDL may reduce the risk of atherothrombosis are increased 
activities of the anticoagulants activated protein C and protein S,35 reduced synthesis of platelet-
activing factor and tissue factor by endothelial cells,36, 37 and neutralization of procoagulatory 
anionic phospholipids.38         
 
Dysfunctional HDL in cardiovascular disease 
Although HDL initially has emerged as a particle with potent atheroprotective properties, more 
recent work demonstrated that HDL is rendered dysfunctional in individuals with 
cardiovascular disease and even may become pro-atherogenic. Already in 2000, Navab et al. 
postulated that atherosclerotic cardiovascular disease is associated with the conversion of HDL 
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from anti-oxidative into dysfunctional pro-oxidative particles.16 The authors revealed that HDL 
particles isolated from coronary artery disease (CAD) patients fail to inhibit oxidation of LDL 
by human arterial wall cells, are unable to prevent the chemotactic effect of LDL on monocytes, 
and do not reduce the ability of LDL-derived oxidize phospholipids to stimulate monocyte 
adherence to endothelial cells, whereas HDL from healthy control subjects show beneficial 
effects.16 Since then, a broad spectrum of dysfunctions of HDL in patients with cardiovascular 
diseases has been described, including a reduced cholesterol efflux capacity from macrophages 
and other cells, impaired anti-oxidative effects, a reduced ability to inhibit adhesion molecule 
expression on endothelial cells, a lack of the normal ability to stimulate endothelial nitric oxide 
bioavailability as well as diminished activities to promote endothelial cell survival.5, 39 There 
are several examples of dysfunction where HDL was not only characterized by loss or reduction 
of normal functionality but by the gain of atypical functions. For example, HDL of patients 
with CAD or chronic kidney disease (CKD) was found to inhibit rather than stimulate nitric 
oxide production because it gained the ability to interact with the lectin-like oxidized LDL 
receptor LOX-1 and the toll-like receptors TLR2 and TLR4, respectively.40, 41 Dysfunctional 
HDL in cardiovascular disease is not limited to CAD and acute coronary syndrome (ACS). Also 
in other cardiovascular diseases, such as heart failure,42 ischaemic cardiomyopathy,43 heart 
transplantion,44, 45 as well as in many conditions that are known to increase cardiovascular risk 
such as diabetes, CKD, acute and chronic inflammatory diseases, or familial 
hypercholesterolemia,46-48 HDL has been found to lose its atheroprotective characteristics. 
Since we have previously reviewed the modifications by disease state,5 we here focus on 
alterations of HDL found in patients with CAD. 
 
Cholesterol efflux capacity as a risk factor for cardiovascular disease 
Several studies investigated the association of present or incident CAD with the capacity of 
apoB-depleted serum or plasma –a surrogate of HDL– to elicit efflux of labeled cholesterol 
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from macrophages. This activity is widely called cholesterol efflux capacity. Various protocols 
have been described that differ by the cell type used and by the use of pharmacological agents 
to investigate specific cholesterol efflux pathways, that is ABCA1-, ABCG1- and/or SR-BI-
mediated cholesterol efflux.  
A pioneering case-control study found that the capacity of apoB-free serum to elicit cholesterol 
efflux from cyclic AMP activated J774 macrophpages is inversely related to carotid intima 
media thickness and associated with decreased odds of having CAD independent of HDL-
cholesterol levels.49 Two case-control cohort studies supported these earlier observations 
regarding the inverse association between cholesterol efflux capacity and prevalent CAD.50  
Several studies have addressed the usefulness of cholesterol efflux capacity as a predictor for 
cardiovascular disease events and got inconsistent findings. The first prospective analysis on 
HDL function reported by Li et al. unexpectedly showed a higher cell-derived cholesterol efflux 
capacity being associated with a higher rather than a lower incident risk for nonfatal myocardial 
infarction/stroke and major adverse cardiovascular events, i.e. nonfatal myocardial infarction, 
nonfatal stroke, or death.50 In contrast, Rohatgi et al, revealed in a biobank of 2924 participants 
from the multiethnic Dallas Heart Study that the risk for future atherosclerotic cardiovascular 
events (nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or death 
from cardiovascular causes) decreases with increasing quartiles of cholesterol efflux capacity.51 
In 2450 probands of the LURIC study who underwent diagnostic coronary angiography, 
cholesterol efflux capacity was also inversely associated with cardiovascular mortality during 
10 years of follow-up.52 In addition, in a nested case-control study from the prospective EPIC-
Norfolk study cholesterol efflux capacity was found to be an independent risk factor for the 
development of fatal or nonfatal CHD.53 However, in renal transplant recipients, baseline 
cholesterol efflux capacity was not associated with future cardiovascular mortality or all-cause 
mortality.54 Of note, in this study low baseline cholesterol efflux capacity was identified as an 
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independent predictor of renal graft failure, a condition, which usually occurs due to progressive 
atherosclerosis in the vasculature of the transplanted kidney.54  
Strikingly, all published prospective studies on HDL function thus far used different methods 
to measure cholesterol efflux capacity. Li et al. used the murine macrophage RAW 264.7 cells 
and cholesterol efflux assays in participants of the Dallas Heart Study, the EPIC-Norfolk Study, 
and the LURIC study were performed with mouse J774 macrophages, whereas in the renal 
transplant recipients study cholesterol efflux capacity was quantified by measuring the efflux 
of labeled cholesterol from human THP-1 macrophages. Because of the stimulation by cyclic 
AMP, the studies on J774 cells and RAW 264.7 cells mainly recorded ABCA1-mediated 
cholesterol efflux, whereas the study on THP1 cells recorded all cholesterol efflux pathways. 
Although the Dallas Heart Study and the EPIC-Norfolk Study both used J774 macrophages and 
although both demonstrated that cholesterol efflux capacity is associated with incident 
cardiovascular disease,51, 53 cholesterol efflux capacity measured with use of fluorescence-
labeled cholesterol (applied in the Dallas Heart Study) only poorly correlated (r = 0.54) with 
measurements performed with radiolabeled cholesterol (applied in the LURIC and EPIC-
Norfolk Studies).51 Vice versa, the capacity of serum to elicit cholesterol efflux from RAW 
264.7 or J774 cells correlated rather strongly (r = 0.92), yet Li et al. did not find any association 
of cholesterol efflux capacity with incident CHD.50 Because of the conflicting results and 
methodological differences, the causal contribution of HDL dysfunction to cardiovascular 
diseases is as yet not proven. The proof will depend on the elaboration of the molecular basis 
of disturbed cholesterol efflux capacity.  
In this context it must also be noted that in the large studies apoB-free serum or plasma rather 
than isolated HDL was incubated with cells for several hours. During this rather long incubation 
time bioactive molecules of the serum or plasma may enter the cell and modify the activity of 
the cellular cholesterol efflux machinery. Notably, the cell surface abundance and activity of 
the cholesterol efflux pump ABCA1 is known to be regulated by free fatty acids, cytokines, and 
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drugs. The cholesterol efflux capacity may hence not only record HDL functionality but also 
adverse regulatory effects of other plasma components on the cells.  
Finally, cholesterol efflux capacity of HDL cannot be taken as a general surrogate of HDL 
functionality because HDL exerts many other functions that are independent of cholesterol 
efflux. These other functions, for example towards endothelial cells, are difficult to be measured 
in large cohort studies.4, 11, 12 Therefore, it is important to unravel the molecular basis of HDL 
dysfunction. The structural correlates of HDL dysfunction, whether HDL-subclasses, proteins 
or lipids or modifications thereof, can be much more easily translated into robust high 
throughput analytical methods than the recording of HDL functionality by cell-based bioassays. 
 
Compositional changes associated with dysfunctional HDLs in cardiovascular disease 
Cardiovascular disease and HDL dysfunction have been associated with changes in the protein 
or lipid composition of HDL (Table 1).  
 
Serum amyloid A 
HDL particles from patients with ACS are enriched in proteins involved in the acute-phase 
response, such as serum amyloid A (SAA) und complement C3.55, 56 SAA is a common acute-
phase protein synthesized by the liver in response to inflammatory cytokines. During an 
inflammatory response, excessive SAA can displace apoA-I from the HDL surface and in 
extreme circumstances SAA can account for up to 80% of the HDL proteins.56, 57 The 
contribution of HDL-bound SAA to HDL dysfunctionality remains a matter of debate. Cell 
culture experiments indicated that the ability of HDL to remove cholesterol from human 
macrophages is only significantly attenuated, when SAA constitutes at least 50% of total protein 
in HDL,58 a situation that is rarely achieved in patients with cardiovascular diseases. Other 
studies have identified SAA as an effective acceptor for cellular cholesterol efflux via SR-BI.59 
Furthermore, SAA-containing acute phase HDL or HDL isolated from mice overexpressing 
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SAA through adenoviral gene transfer efficiently acquired cholesterol from fibroblasts through 
the ABCA1-dependent pathway.59 In sharp contrast, it has been found that acute-phase rabbit 
HDL containing approximately 30% SAA stimulated less cholesterol efflux from J774 
macrophages than native HDL.60 Moreover, in mice, acute inflammation induced by silver 
nitrate impaired the capacity of HDL to promote cholesterol efflux ex vivo.61 This effect was 
not observed in mice lacking SAA1 and SAA2,61 suggesting that SAA1/2 was responsible for 
the decreased HDL cholesterol efflux activities in mice undergoing inflammatory stimulation 
with silver nitrate. Notably, adenoviral overexpression of human SAA1 in mice diminished net 
in vivo reverse cholesterol transport from macrophages to feces.62 One of the mechanisms that 
might contribute to decreased reverse cholesterol transport in response to SAA overexpression 
is the inhibitory effect of SAA on SR-BI-mediated selective uptake of cholesteryl esters from 
HDL.63 Other important functions of HDL that may be influenced by the SAA content are its 
anti-inflammatory, vasoprotective, and anti-oxidative effects. Enrichment of HDL with SAA 
reduced its ability to inhibit thrombin-induced monocyte chemotactic protein-1 expression in 
vascular smooth muscle cells, and in patients with end stage renal disease, the anti-
inflammatory function of HDL correlated inversely with the accumulation of SAA in the 
particle.64 Moreover, it has been demonstrated that native HDL particles supplemented with 
SAA are no longer functional in inhibiting tumor necrosis factor α (TNF-α)-induced expression 
of vascular cell adhesion molecule 1 (VCAM-1) on endothelial cells and subsequent adhesion 
of mononuclear cells.65 However, this was not confirmed by others using artificial reconstituted 
HDL (rHDL).66 Further experiments indicated that SAA-modified HDL lacks the capacity to 
promote endothelial production of nitric oxide.65 Also, SAA-rich HDL loses most of its PON1 
and platelet activating factor acetylhydrolase activity,67 two enzymes that account for the anti-
oxidative potential of HDL. Finally, SAA has been shown to facilitate the retention of HDL by 
vascular proteoglycans,68 which increases its susceptibility to oxidative and enzymatic 
modifications that may render it dysfunctional.  
13 
 
Despite the numerous studies on the influence of SAA on HDL function, it is as yet unclear 
whether the presence of SAA in HDL can lead to an increased risk of cardiovascular disease. 
This issue has been partially addressed in the Ludwigshafen Risk and Cardiovascular Health 
Study, a prospective cohort of 3310 patients referred for coronary angiography.65 In this study, 
higher HDL-cholesterol levels were paradoxically associated with an increased risk of all-cause 
and cardiovascular mortality in patients with SAA concentrations above the 80th percentile,65 
implying that the protective effects of HDL are lost in patients with very high circulating SAA 
levels. 
 
Apolipoprotein C-III 
There is some evidence for a potential role of apoC-III in relation to HDL dysfunction in 
cardiovascular disease. The abundance of apoC-III in HDL particles is increased in subjects 
with CAD and ACS.21, 69-71 Moreover, HDL isolated from patients, who experienced a first 
myocardial infarction before the age of 35, contained elevated levels of apoC-III.72 An analysis 
of data from the Nurses’ Health study and the Health Professionals Follow-Up Study revealed 
an inverse risk association of cholesterol measured in HDL free of apoC-III, but a positive risk 
association with cholesterol measured in apoC-III-containing HDL.73 In this regard it is 
noteworthy that rather prevalent nonsense mutations in the APOC3 gene cause a decrease in 
apoC-III plasma concentrations and triglycerides as well as an increase in HDL-cholesterol. 
Concomitantly, the carriers had an increased chance of CHD-free survival, which was greater 
than expected from the changes in lipoprotein concentrations.74, 75 Some missense mutations in 
APOC3 encode for structural apoC-III mutants, which show reduced abundance in HDL and 
cause a similar lipoprotein phenotype as the nonsense mutations.76 It may hence be that the 
genetically determined lack of apoC-III in HDL improves the functionality and anti-
atherogenicity of HDL.  
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In vitro experiments showed that the presence of apoC-III on HDL impeded its ability to inhibit 
adhesion of THP-1 monocytes to endothelial cells.77 Further proof for a putative involvement 
of apoC-III in HDL dysfunction in cardiovascular disease came from a study demonstrating 
that HDL from CAD and ACS patients are defective in protecting endothelial cells from 
apoptosis.21 The anti-apoptotic capacity of HDL from CAD patients could be restored by a 
blocking antibody for apoC-III, while HDL from healthy subjects no longer suppressed 
apoptosis of endothelial cells after supplementation with apoC-III.21     
 
Triglycerides 
HDL dysfunction in patients with cardiovascular disease, especially in the setting of 
hypertriglyceridemia, may also be driven by an increase in the HDL triglyceride content. The 
high CETP activity in hypertriglyceridemic states favors the net transfer of cholesteryl esters in 
HDL to apoB-containing lipoproteins in exchange for triglycerides, thereby generating 
relatively triglyceride-enriched HDL particles.78 This corroborates with data showing that the 
HDL content of triglycerides is elevated in patients with extensive coronary artery stenosis,79 
in patients after acute myocardial infarction,56 and in patients who had undergone coronary 
artery bypass grafting 34-38 hours previously.80 Concomitant with triglyceride enrichment, the 
level of cholesteryl esters within HDL decreases.79, 80 The effects of triglyceride accumulation 
in HDL on cholesterol efflux are controversial. Some reported an enhanced cholesterol efflux 
capacity in hypertriglyceridemic patients as well as in hyperlipidemic patients in the 
postprandial state, both exhibiting an abnormally high triglyceride content of HDL.81-83 On the 
other hand, it has been demonstrated that the HDL3 subfraction obtained from patients with 
familial hypercholesterolemia was enriched in triglycerides but had a reduced ability to 
mobilize labeled-cholesterol from cultured human macrophages.47 Surprisingly, although 
cellular cholesterol efflux mediated by isolated HDL was reduced in statin-treated coronary 
patients, there was no difference between normolipidemic patients and dyslipidemic patients 
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with low HDL-cholesterol and high triglycerides.84 Of additional interest for the reverse 
cholesterol transport pathway, increased concentrations of triglycerides within HDL were 
shown to interfere with SR-BI-mediated selective uptake of HDL-derived cholesteryl esters in 
hepatocytes.83, 85 Additional studies conducted in patients with familial hypercholesterolemia 
provided evidence that patient HDL enriched in triglycerides is less effective than healthy 
control HDL in inhibiting the release of interleukin-8 (IL-8) from cultured endothelial cells.47 
Nevertheless, it should be noted that all published data so far on the association between HDL 
triglyceride content and HDL dysfunction were obtained using HDL isolated from subjects with 
disease conditions. Hence, the associations between HDL triglycerides and HDL dysfunction 
may simply confound other functionally more relevant changes in the HDL proteome or 
lipidome. Experiments showing the influence of supplementation of HDL with triglycerides on 
HDL functional characteristics are required to definitely establish whether the amount of 
triglycerides within HDL has functional relevance.           
 
Glycerophospholipids 
Lipidomic approaches have identified different phospholipid subclasses on the surface of HDL 
including, -in order of decreasing abundance- phosphatidylcholines, sphingomyelins, 
lysophosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, plasmologens, 
phosphatidylserines, phosphatidylglycerols, phosphatidic acid, and cardiolipins.78, 86 Two 
independent cross-sectional studies in male patients undergoing coronary angiographic 
examination have reported negative associations between serum levels of HDL phospholipids 
and the extent of coronary occlusion.87, 88 Case-control studies applying lipidomics revealed 
statistically significant differences in the composition of phospholipid species between CAD 
patients, ACS patients, and healthy subjects.89, 90   
Variations in the phospholipid composition of the HDL surface lipid monolayer are major 
determinants of the size, net surface charge, and rigidity of HDL particles, all of which may 
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affect their anti-atherosclerotic actions. Particularly, it has been proposed that the physical 
properties of the HDL phospholipid monolayer play a key role in the anti-oxidative function of 
HDL.91 Decreased HDL surface rigidity facilitated the transfer of lipid hydroperoxides from 
LDL to HDL and hence the subsequent inactivation by redox-active Met residues of apoA-I.91 
In fact, most of the phosholipid molecular species identified by liquid-chromatography-mass 
spectrometry/mass spectrometry (LC-MS/MS) profiling of HDL particles could be linked to an 
atheroprotective biological activity of HDL.86 Especially, a strong relationship existed between 
the content of negatively charged phosphatidylserine and various metrics of HDL function, i.e. 
the cholesterol efflux capacity from THP-1 cells, the anti-oxidative activity towards LDL, the 
ability to counteract platelet activation, the anti-inflammatory properties in a cell-free assay, 
and the potential to protect endothelial cells from apoptosis.86  
Artificial enrichment of HDL3 with phosphatidylcholines increased SR-BI-mediated 
cholesterol efflux.92 The same investigators subsequently showed that enhanced in vivo 
hydrolysis of HDL phospholipids by overexpression of endothelial lipase in human apoA-I 
transgenic mice caused pronounced reductions in the serum phospholipid/apoA-I ratio and 
attenuated the capacity of serum to mediate cholesterol efflux via SR-BI by 90%, whereas the 
ABCA1-dependent efflux potential increased by 63%.93 The opposite was observed in mice 
injected with an adenovirus expressing a phosphatidylserine-specific phospholipase.93 
Moreover, the cholesterol efflux capacity of rHDL differed with the phospholipid acyl chain 
length and the degree of unsaturation.94 Also, the magnitude of inhibition of VCAM-1 
expression in activated human umbilical vein endothelial cells varied markedly between 
discoidal rHDL composed of different phospholipid species.95 At equivalent apoA-I molarity, 
rHDL containing 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (PLPC) or 1-
palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine (PAPC) repressed TNF-α-induced 
VCAM-1 expression in endothelial cells by 95% and 70%, respectively, whereas rHDL 
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containing 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) achieved only a 16% 
inhibition.95  
Indirect evidence for an association between HDL dysfunction, HDL phospholipid content, and 
cardiovascular disease, was derived from the results of a clinical study showing that HDL 
isolated from CAD patients with very high HDL-cholesterol levels contained less phospholipids 
and had a lower macrophage cholesterol efflux potential as compared to HDL isolated from 
healthy subjects with very high HDL-cholesterol levels.96 Somewhat contradictory, the 
increased content of lysophosphatidylcholine and phosphatidic acid in HDL from patients with 
an ST-elevation myocardial infarction (STEMI) has been associated with diminished 
cholesterol efflux and anti-oxidative activities.90  
Plasmalogens are a class of glycerophospholipids with anti-oxidative properties that are present 
in HDL only in low amounts.78, 97-99 Patients with CAD had HDL relatively depleted of the 
plasmalogen species PC33:3, PC35:2 and PC34:2 and with a compromised ability to inhibit 
apoptosis of endothelial cells.89 The finding that incorporation of the plasmalogen PC35:2 in 
rHDL improved its anti-apoptotic activity towards endothelial cells further underscored the 
potential importance of plasmalogens for the anti-apoptotic activity of HDL.89         
 
Sphingolipids 
Sphingolipids are represented in HDL by sphingomyelins, ceramides, lysosphingolipids, 
glycosphingolipids, gangliosides, and sulfatides.78  
In animal studies the infusion of rHDL containing the apoA-I mimetic 5A, POPC, and 
sphingomyelin induced more pronounced mobilization of tissue cholesterol and more profound 
plaque regression than sphingomyelin-free control rHDL.100 rHDL containing sphingomyelin 
was also found to be a more potent inhibitor of cytokine release.100 In line with this observation, 
the presence of coronary heart disease in post-menopausal women was inversely related to 
sphingomyelin in HDL.101 
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The lysosphingolipid S1P is probably the most intensively studied sphingolipid of HDL. S1P 
binds to HDL via its specific binding-protein apoM102 and interacts with five different G-protein 
coupled S1P receptors expressed by various cells of the cardiovascular system. HDL also elicits 
efflux of S1P from erythrocytes by apoM-dependent and –independent mechanisms.103 
Although present on only one of 10 to 20 HDL particles, S1P contributes to several of the 
protective functions of HDL. For example, HDL-associated S1P appears to be important for the 
vasoprotective effects on endothelial cell survival,104, 105 endothelial migration,105 endothelial 
adhesion molecule expression,106, 107 endothelial barrier integrity,23, 108 endothelial tube 
formation,109 and nitric oxide-dependent vasorelaxation.20 It also inhibits vascular smooth 
muscle cell migration and chemokine production,31, 110 cardiomyocyte apoptosis during 
hypoxia-reoxygenation,111, 112 and myocardial damage after ischemia/reperfusion.112, 113 Of 
note, at least some functions of S1P appear to be only exerted if S1P is present on HDL.107 This 
is of note because only about 50% of S1P in plasma is transported by HDL. The rest is 
transported by albumin (about 30%) and apoB-containing lipoproteins.102, 114  
Quantification of S1P in apoB-free plasmas of patients with monogenic disorders of HDL 
metabolism have illustrated that very high HDL-cholesterol levels do not automatically 
translate into a higher abundance of S1P in HDL,114 suggesting that measurements of the S1P 
level within HDL may provide additional information beyond plasma levels of HDL-
cholesterol or apoA-I. In fact, initial observational studies suggest that the S1P content of HDL 
is a potential biomarker of cardiovascular disease. One study reported 4 to 5 times higher 
amounts of S1P in HDL of healthy control subjects compared to HDL particles of patients with 
stable CAD.115, 116 Another case-control study also found S1P concentrations lowered in HDL 
of patients with ACS or CAD compared to control HDL, but much less pronounced.89 
Moreover, the concentration of HDL-bound plasma S1P was inversely proportional to the 
severity of angina symptoms in CAD patients.115 In agreement with these data, in patients 
presenting with stable CAD, HDL-bound plasma S1P levels decreased depending on the 
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number of vessels affected by the disease.117 In a nested case control study involving 204 
subjects stratified by HDL-cholesterol from the Copenhagen City Heart Study, S1P levels in 
the HDL-containing fraction of serum (depleted of apoB-containing lipoproteins) were 
inversely associated with the occurrence of ischemic heart disease.108 Although a cross-
sectional analysis in patients with CAD showed that patients who possessed HDL-S1P levels 
in the lowest quartile were more likely to demonstrate in-stent restenosis than patients in the 
higher quartiles,118 the amount of HDL-associated S1P was not predictive for the development 
of restenosis during follow-up in CAD patients after percutaneous coronary intervention.117  
Additional findings of studies on HDL isolated from acute myocardial infarction patients 
suggest that a reduced S1P content of HDL impairs the capacities to stimulate endothelial nitric 
oxide production119 and to inhibit endothelial apoptosis.89 Moreover, a reduced HDL-associated 
S1P content has been related to defects in S1P-dependent activation of ERK1/2 and Akt 
signaling pathways as well as eNOS phosphorylation at Ser1177 in vascular endothelial cells 
in patients with CAD.116 In vitro loading of both healthy and CAD HDL particles with 
additional S1P improved the effects of HDL on endothelial ERK1/2 and Akt activation, eNOS-
activating phosphorylation, and vasorelaxation in pre-contracted arteries.116 This loading may 
not only be an experimental model but may also happen in vivo, because HDL induces S1P 
efflux from erythrocytes and other cells by apoM dependent and –independent mechanisms.103 
It may hence well be that HDL are locally uploaded with S1P by endothelial cells or circulating 
blood cells so that the ex vivo measured S1P levels in HDL underestimate the in vivo situation.  
 
microRNAs 
HDL was also found to contain miRNAs. In vitro experiments showed that HDL delivers 
miRNAs to hamster baby kidney cells and human hepatocytes through SR-BI.9 HDL derived 
from patients with familial hypercholesterolemia or ACS exhibited a miRNA signature pattern 
distinct from that of normal control HDL.9, 10 These findings raised the hypothesis that the 
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miRNA cargo carried by HDL may influence its functionality. The content of miR-223 was 
found increased in HDL isolated from familial hypercholesterolemia subjects.9, 10 Interestingly, 
miR-223 has been described to be a post-transcriptional regulator of various aspects of 
cholesterol metabolism; miR-223 represses the SR-BI-mediated selective uptake of cholesteryl 
esters from HDL and cholesterol biosynthesis and by increasing ABCA1 expression promotes 
cholesterol efflux towards apoA-I.120 HDL was shown to deliver miR-223 into endothelial cells, 
where it downregulates expression of intracellular cell adhesion molecule 1 (ICAM-1).121  
However, these findings are in contrast to those by Wagner et al.10 who confirmed the presence 
of low copy numbers of miRNAs in HDL, but found no evidence that HDL delivers 
physiologically relevant amounts of miRNAs into endothelial cells, smooth muscle cells, and 
peripheral blood mononuclear cells.10 In general, it is important to emphasize the low 
concentration of miRNAs in HDL, which is beyond particle concentration. Many HDL particles 
would need to interact with a single cell to deliver enough miRNA molecules that are sufficient 
for RNA interference. If at all this will more likely happen by autocrine or paracrine regulation 
of neighboring cells rather than by endocrine regulation of distant organs. Further investigation 
is necessary to prove or disprove that HDL-bound miRNAs are of functional importance and 
play a role in the development of cardiovascular disease.  
 
Modifications of HDL components and anti-apoA-I auto-antibodies 
Under inflammatory and oxidative conditions lipids and proteins of HDL undergo certain 
molecular modifications, which directly compromise their beneficial biological properties and 
can produce immunogenic neo-epitopes which trigger the generation of auto-antibodies which 
interfere with HDL function. 
 
Myeloperoxidase-mediated protein modifications 
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Myeloperoxidase (MPO) is a heme enzyme released by neutrophil granulocytes and other 
myeloid cells that can cause protein modifications in HDL (Table 2). In the presence of chloride 
ions and hydrogen peroxide MPO generates the chlorinating intermediate hypochlorous acid 
(HOCl), which can further react with nitrite to generate nitrylchloride.122 Alternatively, MPO 
combines with hydrogen peroxide to convert nitrite into nitric dioxide radicals, which are potent 
nitrating intermediates.122 Previous studies have already introduced MPO as a risk factor for 
cardiovascular diseases. Plasma levels of MPO are elevated early in the course of myocardial 
infarction.123, 124 Moreover, in patients who presented to the emergency department with chest 
pain, circulating MPO levels at presentation predicted acute myocardial infarction as well as 
the need of revascularization, myocardial infarction, and major adverse coronary events in the 
subsequent 30 days and 6 months.123, 124 The preferred target for MPO-catalyzed oxidation in 
HDL is apoA-I. The levels of two MPO-specific oxidation products, 3-nitrotyrosine and 3-
chlorotyrosine, are abundant within apoA-I or HDL particles recovered from either plasma of 
patients with established cardiovascular disease or human atherosclerotic lesions.125-127 In 
apoA-I of circulating HDL, the favored modification site for MPO is tyrosine residue Tyr-
192.128 ApoA-I with nitrated or chlorinated residues Tyr-192, Tyr-18, and Tyr-166 or oxidized 
Trp-72 has also been isolated from human atheroma tissues.128-131 Immunohistochemical 
stainings showed that macrophages in the human atherosclerotic intima are immunoreactive for 
MPO and that the location of immunoreactivities for 3-nitrotyrosine and HOCl-modified 
proteins are closely associated with the presence of apoA-I.126, 127 Moreover, the relative 
proportion of modified apoA-I is much larger in the atherosclerotic plaque than in plasma.128-
130 Taken together, these observations suggest that MPO oxidizes apoA-I in the atherosclerotic 
intima rather than in the circulation.  
Oxidation of apoA-I and HDL with the MPO/H2O2/Cl- system compromised their capacity to 
induce ABCA1-dependent cholesterol efflux.125, 129, 132, 133 Similar experiments using pre-
incubation of apoA-I or HDL with HOCl yielded identical results.127, 132 The marked defect in 
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apoA-I-promoted cholesterol efflux via the ABCA1 pathway following oxidation with MPO 
has been ascribed by some authors to a combination of chlorination of Tyr-192 and methionine 
oxidation.134, 135 In line with this proposal, the extent of chlorination of Tyr-192 and 
sulfoxidation of Met-148 were higher in apoA-I of subjects with stable CAD and ACS and 
inversely correlated with the capacity of serum HDL to remove cellular cholesterol through 
ABCA1.135 Also, apoA-I with oxidative modification of the tryptophan residue Trp-72, a form 
of apoA-I that is highly prevalent in apoA-I recovered from atheroma and increased in the 
plasma of patients with cardiovascular disease or CAD, had significantly lower cholesterol 
acceptor capacity.131 Mechanistically, MPO-dependent chlorination of apoA-I interfered with 
the binding of apoA-I to ABCA1 and as a consequence chlorinated apoA-I failed to activate the 
accompanying JAK2 signaling.132 However, it must be noted that in plasma less than 200 of 1 
million apoA-I molecules contain oxidized Tyr-192 or Trp-72 residues.129, 131 In view of their 
very low quantity it is unlikely that these modifications reduce cholesterol efflux capacity of 
(apoB-free) plasma or HDL by simple loss-of-function in the interaction with ABCA1. Rather 
additional gain of dysfunction is necessary to explain reduced ABCA1-mediated cholesterol 
efflux capacity of plasma by these modifications. The situation is different for sulfoxidized 
Met-148, which is found in up to 30% of apoA-I molecules in plasma. However, in 
atherosclerotic plaques 20% of apoA-I was found to contain oxidized Tyr-192 or Trp-72 
residues,129, 131 so that these modifications may be of local pathogenic relevance independently 
of their impact on cholesterol efflux capacity of plasma. 
Oxidative modification of Met-148 or nitration of Tyr-166 by MPO in apoA-I was also 
associated with a loss of apoA-I-mediated activation of lecithin:cholesterol acyltransferase 
(LCAT),130, 133, 136 which is crucial to help maintain a concentration gradient for cholesterol 
efflux from the cell to the HDL particle surface. The injection of purified MPO into mice 
reduced the net movement of labeled-cholesterol from macrophages to plasma and feces.62 
Fisher’s group demonstrated that the infusion of non-oxidized apoA-I but not apoA-I oxidized 
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by MPO facilitates reverse cholesterol transport from macrophages in apoA-I knockout mice 
and beneficially alters plaque composition in hyperlipidemic apoE knock-out mice.137  
Besides functional consequences for cellular cholesterol efflux and reverse cholesterol 
transport, exposure of human HDL to the MPO/H2O2/Cl- system has also been found to ablate 
the ability of HDL to suppress serum starvation-induced capase-3 activation and thereby 
apoptosis in endothelial cells and to promote eNOS activation.133 Furthermore, HDL modified 
by MPO enhanced rather than inhibited the protein expression of VCAM-1 on endothelial cells 
treated with TNF-α.133 The loss of anti-apoptotic and anti-inflammatory functions of HDL 
following MPO treatment has been explained by the inability of MPO-oxidized HDL to bind 
to SR-BI.133 However, our lab did not find any reduced binding of HDL from CAD patients 
with endothelial dysfunction.40 As discussed before, the very small proportion of apoA-I 
molecules containing MPO-modified amino acid residues is also unlikely to explain the reduced 
endothelial functionality of HDL from CAD patients by loss-of-function in SR-BI interaction. 
By contrast gain-of-dysfunction, for example the atypical interaction with LOX-1,40 can explain 
how quantitatively very minor modifications can lead to endothelial dysfunction.        
 
Protein carbamylation 
Another posttranslational modification of HDL-associated proteins that may actively contribute 
to HDL dysfunction is protein carbamylation. Carbamylation of proteins results from the 
nonenzymatic reaction between isocyanic acid and the ε-amino group of lysine residues or the 
N-terminus of proteins.138 In humans, isocyanic acid is a product of the spontaneous 
decomposition of urea, but at sites of inflammation and atherosclerotic plaques it may also 
derive from the oxidation of thiocyanate by MPO.138, 139 Double immunofluorescence assays 
revealed colocalization of MPO with carbamylated proteins within atherosclerotic plaques.139 
Intriguingly, HDL isolated from human atherosclerotic lesions carried high amounts of 
carbamyllysines.140, 141 These results are consistent with the assumption that HDL trapped in 
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the vascular wall becomes a target for carbamylation. In vitro carbamylation by the 
MPO/thiocyanate/H2O2 system or cyanate has been shown to transform HDL into pro-
atherosclerotic particles. Exposure of aortic endothelial cells to carbamylated HDL induced 
apoptosis of these cells and carbamylated HDL was clearly less potent at preventing endothelial 
apoptosis elicited by growth factor withdrawal.139 Also, HDL particles modified through 
carbamylation not only had poorer cholesterol efflux activities, but instead facilitated further 
accumulation of cholesterol in human monocytes.140 Another important observation is that 
cyanate-treated HDL had lower LCAT activity.141 Additional studies demonstrated that 
carbamalytion reduced the activity of PON1 within HDL and hence the concomitant anti-
oxidative effects of HDL against LDL oxidation.141      
 
Symmetric dimethylarginine 
Symmetric dimethylarginine (SDMA) is the structural isomer of the eNOS inhibitor 
asymmetric dimethylarginine and the concentration of circulating SDMA is an independent 
predictor for cardiovascular mortality in the general population142 as well as in patients with 
CHD.143 The HDL-SDMA content may have important functional implications with respect to 
the vascular effects of HDL. In patients with CKD, SDMA has been found within HDL particles 
and linked to the functional impairment of HDL in these patients.41 HDL from patients with 
CKD and HDL enriched with SDMA inhibited rather than increased endothelial nitric oxide 
production, endothelial cell migration, and endothelial repair as well as stimulated superoxide 
release by endothelial cells, and when injected in mice, raised arterial blood pressure.41  The 
adverse effects of SDMA within HDL on endothelial cells are due to the interaction of SDMA 
with TLR2 on endothelial cells.41 Stimulation of TLR2 by HDL-associated SDMA initiates 
signaling cascades leading to diminished Akt-dependent eNOS-activating phosphorylation at 
Ser473 and increased eNOS-inhibiting phosphorylation at Thr495 as well as activation of 
NADPH oxidase and thereby superoxide production.41  However, these changes were only 
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reported for patients with CKD. As yet, no data are available on the relationship between HDL-
bound SDMA and cardiovascular diseases and their association with HDL dysfunction.  
 
Paraoxonase-1 and lipid peroxidation products  
Several laboratories suggested the inactivation of HDL-associated PON1 as a cause of HDL 
dysfunction in cardiovascular disease. PON1 is an antioxidant enzyme that is carried mostly on 
HDL particles and the positive effects of HDL on LDL oxidation are related to the ability of 
PON1 to hydrolyze lipid peroxides. Additionally, low PON1 activity in HDL may increase the 
susceptibility of HDL to oxidation. The elevated oxidative stress burden in cardiovascular 
diseases may result in the formation of lipid peroxidation products in HDL, which in turn may 
negatively affect their beneficial features. In fact, HDL from mice lacking PON1 were unable 
to prevent the accumulation of lipid peroxides in LDL and these mice demonstrated an 
increased susceptibility to atherosclerosis,144 while introduction of the human PON1 transgene 
in mice had opposite effects on the anti-oxidative functions of HDL and atherosclerosis.145 
Interestingly, if residing on the same HDL particle, PON1 and MPO were found to interact and 
reciprocally affect each other’s enzymatic activity.146 PON1 inhibited MPO peroxidase activity, 
whereas in parallel site-specific oxidative modification of PON1 by MPO impaired PON1 
function.146   
Recent studies linked the loss of endothelial HDL functionality in CAD and ACS patients to 
the increased content of the lipid peroxidation product malondialdehyde (MDA) in HDL due to 
reduced PON1 activity.40  HDL-mediated nitric oxide production in endothelial cells was found 
impaired in patients with either stable CAD or ACS.40 This impairment was the result of 
decreased eNOS-activating phosphorylation at Ser1177 and eNOS-inhibiting phosphorylation 
at Thr495 as well as increased endothelial superoxide production in response to patient HDL.40 
Likewise, HDL from patients with stable CAD and ACS did not inhibit cytokine-induced 
adhesion molecule expression on endothelial cells, induced adhesion of monocytes to 
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endothelial cells under basal conditions, and failed to promote endothelial regrowth after 
arterial injury.40 The adverse effects of HDL from CAD patients on endothelial nitric oxide 
production could be improved by blocking either LOX-1 or protein kinase C βII.40 Modification 
of HDL from healthy control subjects with MDA compromised their ability to induce 
endothelial nitric oxide production via mechanisms involving the activation of LOX-1 and 
protein kinase C βII.40 In addition, heart failure has been associated with the generation of 
dysfunctional pro-inflammatory HDL particles, which increased endothelial release of 
chemotactic activity for monocytes and exhibited reduced PON1 activity.42 The accumulation 
of oxidation products of arachidonic and linoleic acids, presumably attributable to the 
inactivation of PON1, in HDL from patients with heart failure was discussed to contribute to 
the change in functionality.42 There are also data indicating that the concentration of lipid 
peroxidation products is higher in HDL from type 2 diabetic patients with cardiovascular 
disease than in patients with type 2 diabetes but no known cardiovascular disease.147  
 
Anti-apoA-I autoantibodies 
Modifications of apoA-I can give rise to immunogenic neo-epitopes and thus lead to the 
appearance of autoantibodies to apoA-I. Increased levels of anti-apoA-I antibodies were 
initially described in patients with autoimmune diseases, such as systemic lupus erythematosus 
and antiphospholipid syndrome.148 A few years later, Vuilleumier et al. found that 11-21% of 
ACS patients tested positive for anti-apoA-I autoantibodies compared with 20% of patients with 
severe internal carotid stenosis, 38% of non-STEMI patients, 29% of patients undergoing 
elective carotid endarterectomy, and 1-2% of healthy controls.149-152 In fact, there was an 
association between high anti-apoA-I IgG titers and increased circulating levels of oxidized 
LDL, TNF-α, IL-6, IL-8, and matrix metalloproteinase 9 (MMP-9).150, 153, 154 Accordingly, 
patients positive for serum anti-apoA-I IgG had decreased plaque stability, as evidenced by 
increased intraplaque MMP-9 levels as well as higher densities of macrophages and neutrophils 
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within plaques.151 These clinical findings are corroborated by in vivo and in vitro data showing 
that apoE-deficient mice immunized with anti-apoA-I IgG developed larger, more vulnerable 
atherosclerotic lesions with higher neutrophil and MMP-9 contents and reduced collagen 
content, displayed signs of myocardial injury, and had higher mortality rates than apoE-
deficient mice treated with a control IgG.151, 155 Furthermore, incubation of human monocyte-
derived macrophages with anti-apoA-I IgG under cell culture conditions resulted in increased 
production of cytokines (TNF-α, IL-6, IL-8), matrix metalloproteinases (MMP-9), and 
monocyte chemoattractants (CCL2, CXCL8).151, 153, 154 Blocking experiments revealed that 
anti-apoA-I IgG-induced inflammatory responses in macrophages are mediated mainly via the 
CD14/TLR2 complex and to a lesser extent via TLR4.154 Consistent with a role for TLR2 and 
TLR4 in the pro-atherosclerotic effects of anti-apoA-I antibodies, the augmented 
atherosclerotic plaque vulnerability, myocardial necrosis, and mortality in response to anti-
apoA-I IgG passive immunization are abrogated in TLR2- and TLR-4-deficient mice.155 
Moreover, anti-apoA-I autoantibodies exerted a positive chronotropic effect on cultured rat 
cardiomyocytes, potentially explaining the higher resting heart rate observed in ACS patients 
positive for anti-apoA-I IgG.156 Longitudinal analyses established anti-apoA-I IgG positivity as 
an independent predictor of major adverse cardiovascular outcomes in patients with rheumatoid 
arthritis153 as well as one year after hospital admission for myocardial infarction156 or carotid 
endarterectomy.157 Additionally, serum levels of anti-apoA-I could be used to predict the 
presence of coronary artery stenosis in obese but otherwise healthy individuals.158    
 
Functionality of HDL as a potential biomarker in drug development and potential 
therapeutic target 
Traditional HDL-directed therapies of cardiovascular diseases aimed at increasing HDL-
cholesterol levels. However, as described above, HDL loses physiological function and gains 
pathological dysfunction in cardiovascular disease states. Therefore, it might be more effective 
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for the pharmacological treatment and prevention of cardiovascular diseases to improve the 
functionality of HDL particles rather than to increase the concentration of potentially 
dysfunctional HDL. As yet this hypothesis has been tested retrospectively on drugs that are 
already marketed (statins, fibrates, and niacin) as well as in accompanying research programs 
of therapies under development (CETP inhibitors and reconstituted HDL) (Table 3).  
 
Statins 
Statins reduce the burden of CHD mainly if not exclusively by lowering LDL-cholesterol.1 
They have little effect on HDL-cholesterol levels despite affecting the production rate and 
catabolism of HDL. There has been much interest in the effects of statin therapy on the 
functional properties of HDL in cardiovascular disease. As yet the information of clinical 
studies is controversial.  
Treatment of healthy subjects with either pravastatin at a daily dose of 40 mg or atorvastatin at 
daily doses of 10 or 80 mg for 16 weeks was, on average, associated with a 14% increase in the 
functionality of HDL to protect LDL against copper-induced oxidation.159 Moreover, 6-week 
therapy with 40 mg per day simvastatin in patients with coronary heart disease resulted in a 
significant improvement in the ability of HDL to inhibit oxidation and monocyte chemotactic 
activity released by cells after stimulation by oxidized LDL.160 In a small study involving 
dyslipidemic patients, treatment with 2 mg pitavastatin for 4 weeks increased serum 
concentration of HDL-cholesterol levels by 9% and the HDL phospholipid content by 8%.161 
This was accompanied by similar increases in the capacity of the HDL fraction of serum to 
remove cholesterol from human macrophages and HDL-associated PON1 activity.161 Equally, 
a 6-week long treatment with atorvastatin at 10 mg or 40 mg dose-dependently elevated cellular 
free cholesterol efflux towards plasma by 15% and 35%, respectively, in subjects with mixed 
dyslipidemia.162 This improved cholesterol efflux capacity may be the result of the 24% 
increase in apoA-I levels observed following atorvastatin therapy.162 Alternative reasons may 
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be the marked reductions in the CETP-mediated transfer of cholesteryl esters from HDL to 
apoB-containing lipoproteins,162 which at least in animal models has been suggested to be 
atheroprotective.  
In contrast to the aforementioned studies, 16 weeks of therapy with either 10 mg of atorvastatin, 
80 mg of atorvastatin, or 40 mg of pravastatin did not improve the ability of HDL to promote 
cholesterol efflux from macrophages in CAD patients.49 Niesor et al. even reported unfavorable 
properties of statins regarding HDL-facilitated cholesterol efflux.163 Statin exposure of 
cholesterol-loaded human macrophages led to the upregulation of miR-33 mRNA expression, 
reducing both ABCA1 mRNA expression and ABCA1-mediated cholesterol efflux.163 
Interestingly, by the same mechanism, concomitant statin treatment compromised the positive 
effects of other HDL-raising drugs, such as the CETP-inhibitor dalcetrapib, on cholesterol 
efflux capacity.163 Thus, one may speculate that the effects of statins on macrophage miR-33 
expression interfere with the efficacy of CETP inhibitors in statin-treated patients.  
Collectively, these observations account against large benefits of statin therapy on the 
functional properties of HDL, at least if mediated by cholesterol efflux. 
 
Niacin 
Niacin (also known as nicotinic acid or vitamin B3) is an effective agent to improve pro-
atherogenic lipid profiles. In therapeutic doses, niacin can reduce LDL-cholesterol levels by 
15-20% and plasma triglyceride levels by 25-40%, while raising HDL-cholesterol levels by 20-
35%.164 Moreover, extended-release niacin when added to statin monotherapy resulted in 
lowering of lipoprotein(a) and oxidized LDL as well as the inflammatory markers SAA and 
monocyte chemoattractant protein-1.165 As a consequence, like statins, also niacin has attracted 
research interest as a therapeutic candidate for modifying HDL structure and function. In fact, 
mass spectrometry-based proteome analysis revealed that 1 year combination treatment with 
atorvastatin (10 to 20 mg daily) plus extended-release niacin (2 g daily) in CAD patients 
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remodeled the protein composition of HDL3 particles toward that of healthy control subjects.166 
These alterations in HDL structure might contribute to some of the documented effects of 
combined niacin/statin therapy on HDL functions. Sorrentino et al. reported that administration 
of 1500 mg/day extended-release niacin for 3 months in type 2 diabetic patients restored the 
endothelial-vasoprotective properties of HDL and prevented the accumulation of both lipid 
oxidation products and MPO on HDL.167 In correspondence with these findings, 6-week 
therapy with extended-release niacin (0.5 g/day) in individuals with the metabolic syndrome 
caused a moderate improvement in the ability of HDL to suppress VCAM-1 expression and 
increase eNOS protein abundance in endothelial cells.168 Furthermore, apoB-depleted plasma 
from niacin-treated subjects was found to enhance macrophage cholesterol efflux capacity, 
although primarily explained by the elevated HDL-cholesterol concentrations.169 However, 
several recent studies have postulated that niacin does not improve metrics of HDL 
functionality. No differences were observed in the protective effects of HDL against LDL 
oxidation between dyslipidemic patients treated with extended-release niacin/laropiprant on top 
of statin therapy and those treated with statin monotherapy.165 An intervention study in patients 
with dyslipidemia found no significant change in serum cholesterol efflux capacity after 6 
weeks of extended-release niacin therapy (titrated up to 1 g/day).170 Similarly, adding niacin (2 
g daily) to simvastatin therapy provided no additional benefit with regard to cholesterol efflux 
capacity and HDL inflammatory index in patients with carotid atherosclerosis, despite 
increasing HDL-cholesterol by 29%.171  
A placebo-controlled clinical trial by Taylor et al. examined whether extended-release niacin 
slows the progression and/or causes regression of angiographically assessed coronary 
atherosclerosis.172 In patients with CHD or high risk of CHD receiving long-term statin therapy, 
additional treatment with extended-release niacin at a target dose of 2 g daily resulted in a 
regression of mean carotid intima-media thickness over 14 months.172 However, carotid 
regression of subclinical atherosclerosis induced by niacin therapy did not translate into better 
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clinical outcome in both the Atherothrombosis Intervention in Metabolic Syndrome with Low 
HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial173 and the 
Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS-
THRIVE) trial.174 A recent meta-analysis of 387 randomized-control trials implied that niacin 
is effective in reducing the risk of nonfatal myocardial infarction in individuals not treated with 
a statin, whereas on top of background statin treatment niacin failed to reduce cardiovascular 
events.175 Thus, available evidence does not support the routine use of niacin and statin 
combination therapy for the prevention of cardiovascular disease events. The non-unequivocal 
outcomes of the HDL function tests may also reflect the lack of clinical efficacy.            
 
Fibrates  
As activators of the peroxisome proliferator activator receptor alpha (PPAR-α), fibrates regulate 
the expression of several genes with a pivotal role in HDL metabolism, notably apoA-I, ABCA1 
(indirectly via the liver X receptor), phospholipid transfer protein, and SR-BI. Probably because 
the induction of these genes that exert opposite effects on HDL-cholesterol levels, fibrate 
treatment only moderately increases HDL-cholesterol levels. The HDL-cholesterol increasing 
effect is enhanced in patients with elevated triglycerides, which are lowered by fibrate 
treatment. The addition of fenofibrate to statins decreased cardiovascular event rates neither in 
the FIELD trial nor in the ACCORD study, which both included patients with diabetes and 
dyslipidemia.176, 177 According to a recent meta-analysis, fibrates like niacin are effective in 
reducing the risk of nonfatal myocardial infarction in individuals not treated with a statin.175 
However, unlike for niacin post hoc analyses identified a subgroup of patients with both low 
HDL-cholesterol and hypertriglyceridemia who experienced one third less events when treated 
with a combination of statins with fibrates rather than with fibrates alone.178 Also in the absence 
of statins, this subgroup appears to benefit over-proportionately from treatment with bezafibrate 
or gemfibrozil.178  
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Treatment of patients with fenofibrate, bezafibrate, ciprofibrate, or the potent and selective 
PPAR-α agonist LY518674 increased the capacity of total or apoB-free plasma to release 
cholesterol from macrophages in some studies,179-183  but not in others.170, 184 Potential reasons 
are differences in patient populations and cholesterol efflux assays. Notably, ABCA1-mediated 
cholesterol efflux capacity appears to be improved upon fibrate treatment. Interestingly, under 
treatment with LY518674 the changes in ABCA1-mediated cholesterol efflux capacity and 
apoA-I production were found to correlate with one another.179 In mice transgenic for human 
apoA-I, treatment with gemfibrozil or fenofibrate increased the reverse transport from 
macrophages to feces.185  
The effect of fibrate treatment on the anti-oxidative, anti-inflammatory, or endothelial 
functionality of HDL has been less extensively investigated. In diabetic subjects, ciprofibrate 
treatment did not significantly change the ability of HDL to inhibit the oxidation of LDL or the 
expression of monocyte chemotactic protein-1 by human umbilical vein endothelial cells.180 In 
a cross-over-study of 33 patients with mixed hyperlipidemia treatments with fenofibrate and 
niacin were both found to improve the capacity of HDL to enhance nitric oxide production and 
inhibit VCAM-1 expression by endothelial cells.168 Several investigators found that fenofibrate 
treatment increases the activity and concentration of PON1.184, 186, 187  
   
CETP inhibitors 
CETP inhibitors including torcetrapib, dalcetrapib, evacetrapib, and anacetrapib increase HDL-
cholesterol levels by up to 60%, 30%, 120%, and 140%, respectively, and lower LDL-
cholesterol by up to 20%, 0%, 30%, and 40%, respectively. Despite their beneficial effects on 
these lipoprotein traits, three of four large randomized controlled outcome trials on the clinical 
efficacy of add-on-statin therapy with CETP inhibitors have been stopped prematurely because 
of excess cardiovascular and overall mortality (torcetrapib) or futility (dalcetrapib and 
evacetrapib).188, 189, 190 Anacetrapib is the only CETP inhibitor, which is under ongoing phase 
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3 trial investigation for efficacy in preventing clinical endpoints. In the DEFINE (Determining 
the Efficacy and Tolerability of CETP Inhibition with AnacEtrapib) trial including 1623 
patients with known cardiovascular heart disease or at high risk of CHD, co-administration of 
anacetrapib 100 mg once daily with a statin for 24 weeks provided an additional 40% reduction 
in LDL-cholesterol and 138% increase in HDL-cholesterol compared with the statin plus 
placebo group,191 irrespective of the patient subgroup.192 A post hoc analysis found that 2.0% 
of anacetrapib- and 2.6% of placebo-treated subjects experienced a primary end-point at 76 
weeks.191 The ongoing Randomized Evaluation of the Effects of Anacetrapib Through Lipid-
modification (REVEAL) trial that aims to assess whether anacetrapib (100 mg/day) reduces 
cardiovascular events among statin-treated patients with a history of cardiovascular disease is 
ongoing. The results of this study will have to awaited before one can conclude whether CETP 
inhibition in general is the wrong strategy or whether the specific compound or patient groups 
determines clinical utility of CETP inhibition.  
The adverse effect of torcetrapib has been explained by off-target effects on blood pressure. 
This was not seen for dalcetrapib or evacetrapib so that their futility to prevent cardiovascular 
disease events is still not understood. Investigations of both monogenic CETP deficiency and 
polymorphisms in the CETP gene provided controversial evidence. Some studies reported 
reduced cardiovascular disease risk and prolonged life expectancy in individuals with CETP 
mutants,193-196 others did not find any impact or even increased cardiovascular risk.197, 198 
Previous meta-analyses of genetic studies, provided compelling evidence that polymorphisms 
that are associated with reduced CETP activity and increased HDL-cholesterol levels are also 
associated with reduced cardiovascular risk.199, 200 Another recent meta-analysis of this 
Mendelian randomization approach, however, conversely found, that a specific increase in 
circulating HDL-cholesterol levels due to the Taq1B polymorphism in the CETP gene was not 
associated with a lower risk of developing CAD.201 Population studies that investigated CETP 
plasma concentrations as a biomarker also yielded results that contradict the initial genetic 
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studies: Low rather than high CETP concentrations were associated with increased 
cardiovascular mortality in a nearly 8 years long follow-up of more than 3000 patients who 
underwent coronary angiography.202 In the PROVE IT-TIMI 22 study, plasma CETP levels 
were not associated with differences in  cardiovascular event rates. In the 50% of patients who 
reached the lowest concentrations of LDL-cholesterol by pravastatin treatment, a low CETP 
concentration was associated with excess cardiovascular event rates.203 It hence remains 
questionable whether lowering of CETP activity at least later in life or in combination with 
statin therapy reduces cardiovascular risk despite increasing HDL-cholesterol and decreasing 
LDL-cholesterol.  
Animal models provided controversial data on the role of CETP in atherosclerosis. Wild-type 
mice lack CETP, so that only the effect of transgenic CETP overexpression on atherosclerosis 
could be investigated. In wild-type mice as well as in hypercholesterolemic mouse models, 
overexpression of CETP increased atherosclerosis.204, 205 By contrast, in hypertriglyceridemic 
mouse models and in mice overexpressing LCAT, CETP overexpression reduced 
atherosclerosis despite lowering HDL-cholesterol.204, 205 In rabbits, vaccination against 
CETP206 as well as CETP inhibition with either JTT705 (= dalcetrapib),207 torcetrapib,208 or 
antisense-nucleotides209 were found to increase HDL-cholesterol and reduce atherosclerosis. 
Most studies regarding HDL functionality investigated the impact of CETP inhibitors on 
cholesterol efflux capacity as well as the delivery of cholesteryl esters to hepatocytes in vitro 
as well as macrophage reverse cholesterol transport in animals. In general these activities were 
improved by the application of a CETP inhibitor. There is limited information on the impact of 
CETP inhibition on anti-inflammatory or endothelial functionalities of HDL. 
Torcetrapib: Cholesterol efflux from THP-1 macrophages to apoB-depleted plasma of subjects 
with moderate hypercholesterolemia without cardiovascular disease was higher among patients 
treated with 60 or 120 mg torcetrapib for 8 weeks, and at least for the higher dose this effect 
was independent of increases in HDL-cholesterol levels.210 In agreement with these 
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observations, in male subjects with high-risk HDL-cholesterol levels (<40 mg/dl), 6-week 
combination treatment with torcetrapib (60 mg/day) and atorvastatin (10 mg/day) enhanced the 
capacity of large HDL2 particles to mediate cholesterol efflux via SR-BI and the delivery of 
HDL cholesteryl esters to hepatoma cells when compared to atorvastatin monotherapy.211 
Similar findings were reported from a study in patients with mixed hyperlipidemia where 
HDL2-mediated cholesterol efflux and uptake of HDL cholesteryl esters by hepatocytes were 
shown to be augmented by a 6-week period of combined torcetrapib/atorvastatin (60/10 
mg/day) therapy.212 The treatment of hamsters with torcetrapib increased the mobilization of 
radiolabeled cholesterol from peritoneal macrophages into plasma HDL and subsequent 
excretion into stool.213, 214  
Dalcetrapib: Results of a phase IIb study comparing different doses of dalcetrapib in 
dyslipidemic patients treated with pravastatin (40 mg/day) indicated a positive effect of 
dalcetrapib on ABCA1- and SR-BI-mediated cellular cholesterol removal.215 Likewise, in the 
dal-ACUTE study that enrolled 300 patients who had a recent ACS, dalcetrapib at a daily dose 
of 600 mg enhanced the capacity of apoB-depleted plasma to elicit non-ABCA1-specific 
cholesterol efflux from macrophage foam cells, which was related to changes in apoA-I and 
HDL-cholesterol levels.216 In normolipidemic hamsters, dalcetrapib promoted the fecal 
elimination of macrophage-derived cholesterol,214 but in high-fat-induced hyperlipidemic 
hamsters the effect was in the opposite direction, with dalcetrapib limiting the excretion of 
macrophage cholesterol.217 Dalcetrapib treatment did not restore the reduced ability of HDL 
from CHD patients to stimulate endothelial nitric oxide production and to inhibit apoptosis and 
VCAM-1 expression of endothelial cells.218 In a recent post hoc analysis of the dal-
OUTCOMES trial, Tardif et al. revealed that genetic differences in the adenylate cyclase 9 
(ADCY9) locus stratifies recipients of dalcetrapib  towards  cardiovascular outcome.219 
Dalcetrapib treatment decreased the cardiovascular event rate by 39% in patients with the AA 
genotype at rs1967309 but increased cardiovascular event rates by 27% in patients with the GG 
36 
 
genotype.219 The ADCY9 gene encodes an adenylate cyclase that catalyzes the formation of the 
signaling molecule cAMP from ATP. Since cAMP regulates ABCA1, Tardiff et al. 
hypothesized that the ADCY9 gene trans-regulates ABCA1 activity, which may in turn 
determine the translation of dalcetrapib-induced changes in HDL metabolism into 
cardiovascular efficacy. Alternatively, since adenylate cyclases are downstream targets of G-
protein-coupled receptors (GPCRs) and since HDL components such as S1P interact with 
GPCRs, it is tempting to speculate that HDL-induced signaling pathways could be potentially 
affected by the polymorphism in the ADCY9 gene. Depending on the functionality of the 
agonist, the mutation may promote beneficial effects of physiological HDL or abrogate adverse 
effects of dysfunctional HDL.    
Anacetrapib: HDL from dyslipidemic patients, who received anacetrapib 300 mg/day for 8 
weeks, were more potent at promoting net transfer of cholesterol out of macrophage foam cells 
than HDL from placebo-treated patients.169 These results are consistent with the stimulatory 
effects of anacetrapib on macrophage-to-feces reverse cholesterol transport in both 
normolipidemic and dyslipidemic hamsters.217, 220 Anacetrapib treatment in dyslipidemic 
hamsters and healthy human volunteers had no effect on the ability of HDL to blunt cytokine-
induced expression of adhesion molecules and monocyte chemotactic protein-1 in endothelial 
cells.221 
Overall these data indicate that CETP inhibition improves cholesterol efflux capacity of plasma 
but does not alter anti-inflammatory or endothelium-protective activities of HDL.  
 
HDL mimetics  
HDL-like discoidal particles can be artificially reconstituted by the use of water soluble 
apolipoproteins, notably apoA-I or apoE, or even amphipathic peptides.7, 222, 223 In cell culture 
experiments these rHDL particles imitate several potentially anti-atherogenic effects of native 
HDL, notably the induction of cholesterol efflux from macrophage foam cells as well as the 
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stimulation of nitric oxide production and the inhibition of VCAM-1 expression and apoptosis 
by endothelial cells. In animal models of atherosclerosis, infusion of rHDL prevented the 
development of atherosclerosis or even caused regression of atherosclerosis.222, 223 At least three 
formulations of rHDL have entered clinical development and have been applied to humans:  
- CSL111 and its successor CSL112 consist of native apoA-I and phosphatidylcholines 
isolated from human plasma and soybean, respectively.7, 222, 223 In the ERASE trial of 
186 patients with ACS 2 weeks before, four weekly infusions of 40 mg CSL111/kg 
body weight induced a reduction of coronary atheroma volume as assessed by 
intravascular ultrasound (IVUS), which was statistical significant compared to baseline 
but not compared to placebo.224 The infusion of CSL111 was also found to improve 
endothelial dysfunction, platelet function, and glycaemia in patients with type 2 diabetes 
mellitus.32, 225-227 Both total and apoB-free plasma of probands infused with CSL111 
showed increased cholesterol efflux capacity.228, 229 The relative increase in cholesterol 
efflux capacity was even higher in total plasma than in apoB-free plasma (the surrogate 
of HDL),230 reinforcing the previous notion that apoB-containing lipoproteins enhance 
the cholesterol efflux elicited by HDL through cycling of cell-derived cholesterol 
between cells and HDL.229, 230 As lipid-containing particles, rHDL directly enhances 
cholesterol efflux via the SR-BI and ABCG1-mediated pathways. Indirectly however, 
it also appears to enhance ABCA1-mediated cholesterol efflux. Phase 1 studies on the 
second generation product CSL112 revealed that the infusion of rHDL increases the 
formation of prebeta-HDL (that is lipid-free apoA-I) by a factor 36 and, probably as the 
result, the capacity of plasma to elicit ABCA1-mediated cholesterol efflux in vitro by 
270%.231 HDL from plasma of probands treated with CSL111 showed increased anti-
inflammatory capacities to inhibit the expression of VCAM-1 and ICAM-1 by 
endothelial cells as well as the expression of CD11b by monocytes and the adhesion of 
neutrophils to a fibrinogen matrix.228  
38 
 
- ETC-215 which is now further developed as MDCO-216 contains the apoA-
I(R173C)Milano variant and palmitoyloleylcholine.7, 222, 223 Compared to wild-type apoA-
I containing rHDL, rHDL with apoA-I(R173C)Milano showed more potent cholesterol 
efflux-stimulating as well as anti-inflammatory capacities.232 Like rHDL containing 
wild type apoA-I, ETC-215 induced the regression of atherosclerosis in both rabbit and 
mouse models of atherosclerosis.7, 222, 223 In a phase 2 study of 57 patients, five weekly 
ETC-215 infusions two weeks after ACS caused significant regression of IVUS-
assessed total atheroma volume in coronary arteries compared to baseline.233 Infusion 
of MDCO-216 into cynomolgous monkeys increased the capacity of plasma to induce 
cholesterol efflux via the ABCA1 pathway much more prominently than via the ABCG1 
and SR-BI pathways, probably by displacing endogenous wild-type apoA-I from 
endogenous HDL and thereby enhancing the formation of prebeta1-HDL.234 A similar 
effect was seen ex vivo, when MDCO-216 was mixed with human plasma.235 
- CER-001 is the third formulation of rHDL that has entered clinical evaluation in 
humans. It contains recombinant apoA-I, diphosphatidylglycerol, and 
sphingomyelin.236 The presence of sphingomyelin appears to enhance the cholesterol 
efflux capacity of both the rHDL itself and the plasma containing rHDL.236 In an open 
label study of seven patients with familial low HDL cholesterol syndromes (familial 
hypoalphalipoproteinemia), 9 infusions of 8 mg/kg body weight CER-001 led to a 
significant regression of carotid atherosclerosis as assessed by NMR.237 At the same 
time the cholesterol efflux capacity of plasma was significantly increased compared to 
baseline. Also the fecal sterol excretion was increased, however not significantly (P = 
0.068).237 In 23 patients with homozygous familial hypercholesterolemia, 12 biweekly 
infusions of CER-001 led to a significant reduction in carotid mean vessel wall area 
after 24 weeks.238 In a randomized controlled trial of 500 ACS patients six weekly 
infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001 had significant impact 
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neither on IVUS assessed coronary atheroma volume nor angiography assessed severity 
or extent of CHD.239 
 
Conclusions 
HDL functionality has potential implications for diagnostics as well as therapy and hence 
biomarker discovery and drug development. 
 
Diagnostics and biomarker discovery  
Because of the failures of the recent trials on fenofibrate, niacin, torcetrapib, dalcetrapib, and 
most recently evacetrapib, but also because of lacking genetic association of HDL cholesterol 
with cardiovascular risk, changes in HDL cholesterol are no longer considered as a surrogate 
marker for drug development. Previously, HDL function has rather been a subordinate endpoint 
in drug development. This appears to change, although there is as yet no evidence on the ideal 
HDL function test. The exact role and hence clinical importance of dysfunctional HDL in the 
pathogenesis of cardiovascular diseases is still unclear because of three main reasons:  
First, most dysfunctions have been identified by small exploratory case-control studies which 
aimed at the identification of causes and effects of HDL dysfunction on the molecular level. 
With the exception of cholesterol efflux capacity no dysfunction has been investigated in large 
cross-sectional or even longitudinal studies for diagnostic and prognostic performance, 
respectively. To this end the HDL function tests must be not only technically feasible for high 
throughput, but also analytically robust, and pre-analytically controlled. As yet only data on the 
analytical performance of cholesterol efflux capacity, and HDL-induced nitric oxide and 
superoxide production in endothelial cells as well as serum PON1 activity have been published. 
These assays appear to work reproducibly at least within individual specialized labs.49-51, 240 
Accuracy is difficult to assess because there is no gold standard. Cholesterol efflux capacity 
appears to be strongly influenced by the method used.50, 51 For other functions no method 
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comparisons have been reported. The intraindividual variability of cholesterol efflux capacity, 
HDL-induced nitric oxide and superoxide production in endothelial cells as well as serum 
PON1 activity within one day, one week and one month was found very low.49, 51, 240   Neither 
did sample storage affect the measurement of cholesterol efflux capacity significantly.49 Graded 
by stages of biomarker development241 and in comparison with established and other emerging 
biomarkers of HDL metabolism, HDL function tests are in a rather early phase of development 
with cholesterol efflux capacity being most advanced (Table 4). 
Second, the relative importance of the many functions of normal HDL from healthy individuals 
and many dysfunctions of pathological HDL for the pathogenesis of atherosclerosis is not 
known. The present scientific literature is dominated by studies that record cholesterol efflux 
capacity. This does not only reflect the fact that the mediation of cholesterol efflux is the 
classical anti-atherogenic function but also feasibility: it is performed on total or apoB-free 
serum and thereby avoids the laborious and also artefact-prone isolation of HDL by 
ultracentrifugation.242 However, the increase in cholesterol efflux capacity but lack of clinical 
efficacy by treatment with torcetrapib and dalcetrapib (cf. Table 3) indirectly questions the 
feasibility of this bioassay to aid in drug development or monitor treatment success. The 
unchanged endothelial and anti-inflammatory functionalities of HDL appear to be in better 
accordance. Systematic head to head comparisons are needed to establish the HDL functionality 
which has the strongest association with CHD and treatment response and is therefore likely 
most relevant for the anti-atherogenicity of HDL. 
Third, structure-function-relationships of HDL function and dysfunction are not 
comprehensively elaborated. There are many examples of functions and dysfunctions that have 
been associated with different molecules within HDL. For example the ability of normal HDL 
to stimulate nitric oxide production in endothelial cells has been assigned to pure apoA-
I/phospholipid complexes 222, 223 as well as to minor constituents such as S1P.20 Endothelial 
HDL dysfunction has been assigned to the loss of S1P,119 oxidative modifications of apoA-I or 
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phospholipids,40 enrichment with SAA65 or SDMA.41 Likewise, differences in cholesterol 
efflux capacity have been attributed to differences in HDL particle number, HDL subclass 
distribution, phospholipid composition,86 the presence of SAA,58-61 or posttranslational 
modifications.127-132 As yet it is not clear whether these findings reflect redundancy or 
complexity of HDL interactions with endothelial cells or result from confounding.  
The solution of these three general problems is pivotal for the targeting of HDL dysfunction by 
both biomarkers for improved diagnostics and therapy.  Systems biological approaches with 
comprehensive characterization of HDL structure and composition as well as functionality are 
needed to resolve this question. Such an approach may lead to the identification of pivotal 
molecules that to a large extent differentiate functional and dysfunctional HDL and can hence 
be used as biomarkers for drug development and monitoring of treatment success. 
 
Therapy and drug development  
The active components and the downstream cellular responders of both functional HDL and 
dysfunctional HDL are interesting targets for drug development towards treatment or 
prevention of CHD. In this regard it is again pivotal to establish the most relevant functions and 
the structural correlates of HDL in the pathogenesis of atherosclerosis. Mediators of 
physiological protective functions would need activation, whereas mediators of HDL 
dysfunction would need inhibition. It is hence crucial to establish whether changes in the 
functionality of HDL under inflammatory conditions are caused by loss of function or gain of 
dysfunction (Figure 2). Loss of functional HDL components would need replenishment or 
activation. Gain of dysfunction will require the elimination of harmful components or blockage 
of their formation and their cellular responders. In this situation, although at first sight 
paradoxically, therapies that enhance the catabolism of HDL and thereby lower HDL 
cholesterol, such as probucol243 or testosterone,244 will be rather beneficial. Such therapies may 
benefit from combination with HDL mimetics or stimulators of HDL production. Also drugs 
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that induce both HDL production and HDL catabolism, such as fibrates or statins, will be good 
candidates although they do not alter HDL-cholesterol levels much. Any therapy that prolongs 
the residence time of HDL with gained adverse function, for example CETP inhibitors or 
estrogens, will be damaging rather than beneficial, although they increase HDL-cholesterol 
levels. 
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Legends to the figures 
 
Figure 1: Principle physiological structure-function-relationships of normal HDL. HDL 
are heterogenous particles differing by size shape and composition of proteins, lipids, and 
microRNAs. HDL and its components elicit cellular responses either by modulating cholesterol 
homeostasis through cholesterol efflux or by specific interactions with signalling receptors (for 
example activation of S1P receptors by S1P or the ecto-ATPase/purinergic receptor axis by 
apoA-I).  Either principle mechanism can lead to posttranslational short term effects or rather 
transcriptional long term effects and thereby alter the function and survival of cells. ABC’s = 
ATP-binding cassette transporters; GPCR = G-protein coupled receptor; SR-BI = scavenger 
receptor class B type I.  
 
Figure 2: Principle structure-function-relationships of pathological HDL. Modifications in 
the composition of HDL or structural alterations of the HDL components can produce either 
loss of physiological functions or gain of pathological dysfunction. The former compromises 
the physiological interactions with cells described in Figure 1. The latter generates novel 
interactions, for example with pattern recognition receptors such as toll-like receptor 2 (TLR2) 
or lectin-like oxidized receptor 1 (LOX-1). For comparison and explanations of other 
abbreviations see Figure 1.  
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Table 1: Effects of compositional changes in high-density lipoproteins (HDL) on HDL function 
 
Modification Functional impact Potential mechanism References 
SAA-enrichment ↓ Cholesterol efflux capacity 
↓ Macrophage reverse cholesterol transport 
↓ Inhibition of MCP-1 
Disturbed endothelial function: - No inhibition of VCAM-1 expression - No inhibition of monocyte adhesion to ECs - No stimulation of NO production 
↓ Anti-oxidative activity 
Proteoglycan retention 
↓ Cholesterol efflux and SR-BI-mediated selective uptake of HDL-CE 
↑ FPR2-mediated signaling 
 
 
↑ MCP-1 and VCAM-1 expression 
 
↓ PON1 and PAF-AH activity 
60, 61, 68 
62, 63 
64 
65 
 
 
 
67 
ApoC-III-enrichment Disturbed endothelial function: - No inhibition of monocyte adhesion to ECs - ↓ Inhibition of endothelial apoptosis  ↑ Phosphorylation of p38-MAPK and proapoptotic tBid expression  77 21 
Triglyceride-enrichment ↓ Cholesterol efflux capacity 
↓ SR-BI-mediated selective uptake of HDL-CE 
↓ Inhibition of IL-8 release from ECs 
 
Competition of HDL-TG with HDL-CE for selective uptake by SR-BI 
47 
83, 85 
47 
Sphingomyelin-depletion ↓ Anti-oxidative activity 
↓ Cholesterol efflux capacity 
↓ Inhibition of cytokine release 
↑ HDL surface lipid rigidity 91 
100 
100 
Phosphatidylserine-
enrichment 
↑ Cholesterol efflux capacity 
↑ Inhibition of LDL oxidation 
↑ Inhibition of platelet activation 
↑ Anti-inflammatory activity 
↑ Inhibition of endothelial apoptosis 
↑ Negative HDL surface charge 86 
Phosphatidylcholine-
enrichment 
↑ Cholesterol efflux capacity ↑ Solubilization of desorbed cholesterol molecules 
 
86, 92 
Lysophosphatidylcholine-
enrichment 
↓ Cholesterol efflux capacity 
↓ Inhibition of LDL oxidation 
Dissociation of apoA-I from HDL 90 
Phosphatidic acid-
enrichment 
↓ Cholesterol efflux capacity  90 
Plasmalogen PC35:2-
enrichment 
↑ Inhibition of endothelial apoptosis Scavenging of oxygen radicals, reduction of cholesterol oxidation by 
free radicals, or delayed oxidation of polyunsaturated fatty acids 
89 
S1P-depletion Disturbed endothelial function: - ↓ eNOS activation and stimulation of NO 
production - ↓ Vasodilator  potency 
 
↓ ERK1/2 and Akt signaling 
 
↓ NO production 
 
116, 119 
 
116 
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- ↓ Inhibition of endothelial apoptosis - ↓ Endothelial barrier function  89 108 
SDMA-enrichment Disturbed endothelial function: - Inhibition of NO production - ↓ Stimulation of EC migration - ↓ Stimulation of endothelial repair - ↑ VCAM-1 expression - ↑ Superoxide production 
↑ Blood pressure in mice 
Activation of endothelial TLR2-signaling: 
↓ eNOS-activating phosphorylation, ↑ eNOS-inhibiting 
phosphorylation 
 
 
 
Activation of NADPH oxidase 
41 
MDA-enrichment Disturbed endothelial function: - ↓ Stimulation of NO production  Activation of LOX-1 and protein kinase C β3 40 
Abbreviations used: Apo = apolipoprotein; CE = cholesteryl ester; EC = endothelial cell; eNOS = endothelial nitric oxide synthase; FPR2 = formyl-peptide receptor 2; IL-8= interleukin-8; LDL = low-density lipoprotein; 
LOX-1 = lectin-like oxidized LDL receptor; MCP-1 = monocyte chemotactic protein-1; MDA = malondialdehyde; NO = nitric oxide; PON1 = paraoxonase 1; PAF-AH = platelet activating factor acetylhydrolase; S1P = 
sphingosine-1-phosphate; SAA = serum amyloid A; SDMA = symmetric dimethylarginine; SR-BI = scavenger receptor class B type I; TG = triglyceride; TLR2 = toll-like receptor 2; VCAM-1 = vascular cell adhesion 
molecule 1  
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Table 2: Major amino acid residues in apolipoprotein (apo)A-I modified by myeloperoxidase (MPO) and effects on HDL function 
 
Amino acid residue in 
apoA-I 
Preferred 
modification 
Functional impact Proportion of apoA-I molecules 
modified 
Causal role in apoA-I 
dysfunction 
Tyr-192 Chlorination ↓ Cholesterol efflux capacity 
 
Plasma: <0.02% 
Plaque: 20% 
Unclear 
Tyr-166 Nitration = Cholesterol efflux capacity  
↓ Stimulation of LCAT activity 
Plasma: 0.14% 
Plaque: 8% 
Unclear 
Trp-72 Oxidation ↓ Cholesterol efflux capacity 
↓ Stimulation of LCAT activity 
Loss of HDL biogenesis activity in vivo 
↑ VCAM-1 protein expression on ECs 
↑ Nuclear translocation of NF-κB in ECs 
Plasma: 0.007% 
Plaque: 20% 
Yes 
Met-148 Sulfoxidation ↓ Cholesterol efflux capacity 
↓ Stimulation of LCAT activity 
Plasma: 30% 
Plaque: ? 
Unclear 
Abbreviations used: EC = endothelial cell; HDL = high-density lipoprotein; LCAT = lecithin-cholesterol acyltransferase; Met = methionine; Tyr = tyrosine; Trp = tryptophan; VCAM-1 = vascular cell adhesion molecule 1  
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Table 3: Effects of lipid modifying drugs on high-density lipoprotein (HDL) cholesterol, HDL function and cardiovascular disease 
 
 statins fibrates niacin CETP inhibitors HDL mimetics 
HDL cholesterol level No or little effect Increase by 5 to 15% Increase by 10 to 35% Increase by 25% 
(dalcetrapib)  
to 130% (anacetrapib) 
No persistent increase  
Cholesterol efflux 
capacity 
No consistent effect Increased ABCA1-
dependent efflux 
No effect independently of 
HDL cholesterol 
Increased ABCA1-
dependent and ABCA1-
independent efflux 
increased ABCA1-
dependent and ABCA1-
independent efflux 
Anti-oxidant activities Possibly increased PON1 
activity 
No effect on PON1 No effect on PON1 ? ? 
Endothelial functionality ? Increased stimulation of 
eNOS and inhibition of 
VCAM-1  
Increased stimulation of 
eNOS and inhibition of 
VCAM-1 
No change in eNOS 
stimulation or inhibition of 
VCAM-1 or apoptosis 
Increased inhibition of 
VCAM-1 by CSL111 
      
Extent of atherosclerosis Reduced progression.  
Regression upon Intensive 
treatment 
Reduced progression Reduced progression.   No change by torcetrapib 
or dalcetrapib. Evacetrapib 
and anacytrapib unkonwn 
Controversial evidence  
Cardiovascular endpoints Reduction of 
cardiovascular morbidity 
and mortality as well as 
total mortality 
Reduced cardiovascular 
morbidity in the absence 
of statins; no effect if 
combined with statins 
Reduced cardiovascular 
mortality in the absence of 
statins; no effect if 
combined with statins 
Increased cardiovascular 
morbidity and total 
mortality by torcetrapib,  
lack of effect by 
dalcetrapib or evacetrapib, 
anacetrapib unknown 
Not known 
Abbreviations used: ABCA1 = ATP-binding cassette transport A1; eNOS = endothelial nitric oxide synthase; PON1 = paraoxonase 1; VCAM-1 = vascular cell adhesion molecule 1. 
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Table 4: Rating of high-density lipoprotein (HDL)-related biomarkers according to clinical utility criteria241, 242 
 
 HDL 
cholesterol 
apoA-I  HDL particle 
number  
HDL subclasses Cholesterol efflux 
capacity  
Anti-oxidative 
capacity (PON1) 
Endothelial 
function 
Analytical performance  
Precise assays Yes Yes (yes) (yes) yes yes Yes 
Accurate/method-independent 
assays? 
Not optimal Yes (yes) No no PON1 yes Unknown 
Pre-analytical issues clarified? Yes Yes (yes) (yes) (yes) (yes) (yes) 
Accessible assays? Yes Yes no No no No  
(PON1 activity 
feasible) 
no 
High throughput and rapid 
turn-around-time? 
Yes Yes Within a center 
yes, 
 otherwise no 
Within a center by 
NMR yes, 
otherwise no 
no No  
(PON1 activity 
feasible) 
No 
Reasonable costs? Yes Yes ? ? no ?  
(PON1 activity 
feasible) 
no 
Diagnostic / prognostic 
performance  
 
Robust association with 
incident disease? 
Yes Yes yes No (Yes) PON1 No, 
otherwise 
unknown 
Unknown 
Novel information beyond 
existing biomarkers? 
(reference) No (yes) No In positive studies 
yes 
PON1 No, 
otherwise 
unknown 
Unknown 
Validated decision limits? Yes No no No No No no 
Clinical utility  
Superiority to existing tests? (Reference) No Possibly Unknown Unknown Unknown Unknown 
Modifiable risk association  
(treatment target)? 
No Unknown Unknown Unknown Unknown Unknown Unknown 
Biomarker guided triage 
enhances care? 
yes unknown unknown Unknown unknown unknown unknown 
Abbreviations used: apo = apolipoprotein; PON1 = paraoxonase 1 
 
 
